Business Wire

WHOOP and Samuel Ross MBE Announce Multiyear, Global Creative Partnership, Introducing a New Era in Performance Fashion

15.1.2026 13:00:00 CET | Business Wire | Press Release

Share

WHOOP, the human performance company, announces a landmark creative partnership with acclaimed designer Samuel Ross MBE, who joins as Global Creative Director, WHOOP x SR_A to lead a multiyear collaboration between the two brands titled PROJECT TERRAIN. The collaboration signals the ongoing evolution of WHOOP from a pioneering wearable technology company into a brand shaping not just the future of personal health but also its intersection with performance fashion and cultural design.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115643104/en/

WHOOP and Samuel Ross MBE Announce Multiyear, Global Creative Partnership, Introducing a New Era in Performance Fashion

As the first performance design collaboration for WHOOP, the partnership represents a new chapter for the brand. Under Ross’ direction, PROJECT TERRAIN will deliver a bespoke capsule collection including limited-edition, customized WHOOP bands. The range will also include new apparel pieces within the WHOOP Body collection, technical garments that enable wearing WHOOP beyond the wrist, arriving in limited edition drops this year and into 2028.

Under the moniker of his award winning design studio, SR_A (previously notably founding A-Cold-Wall*), Ross’ work spans forty footwear models with Nike and Converse, Oakley across three collections, five years of product partnerships with LVMH via Hublot watch designs and experimental fragrances with Acqua di Parma, to the first external design role within Apple Group as Principal Design Consultant at Beats. He has consistently reimagined how culture, material science, and form influence one another. His transition into performance innovation with WHOOP represents a natural progression for an industrial designer whose work centers on precision, human movement, and the evolution of contemporary aesthetics. Ross has worn WHOOP for five years, forming an immediate, authentic connection to its design, culture, and technology.

“At WHOOP, we've always believed that wearable technology needs to be invisible or it needs to be cool,” said Will Ahmed, Founder and CEO of WHOOP. “Working with Samuel Ross has been a true joy. He deeply understands wearable technology. Our members will feel something new and different when they wear this limited collection.”

Speaking of the joint venture, Johan Liden, Chief Creative Officer of WHOOP, said, “Design has always been core to how WHOOP delivers meaningful impact, and Samuel brings a level of craft and provocation that pushes that mission even further. His approach to materials, form, and function aligns perfectly with our ambition to create products that are both deeply technical and emotionally resonant. Our collaboration enables us to expand the WHOOP design language into an entirely new dimension—one that empowers members to experience performance and self-expression in ways they never have before.”

The Creative Vision Behind PROJECT TERRAIN

SR_A’s industrial and architectural ethos will define the visual and tactile identity of the upcoming WHOOP x SR_A capsule, PROJECT TERRAIN. The studio’s commitment to precision, material innovation, and functional clarity introduces a new design vocabulary for WHOOP, informed by utility, intentionality, and structural, materials-driven design approach.

Samuel Ross, Global Creative Director, WHOOP x SR_A, said, “WHOOP is shaping the future. That’s true progress, for all. It is one of the first design and technology companies of our generation, founded within our generation, by our generation, that is defining the right relationship to health, through advanced technology. I look forward to building the future with Will and the WHOOP design teams. We have a clear, sharp vision to move global design expectations forward.”

“This landmark joint venture reflects our shared vision for the future of wearable technology and the power of innovation and creativity,” said Yi Ng, Co-founder and CEO of SR_A. “As an industry first, it underscores our mutual commitment to pushing boundaries. Partnering with WHOOP enables us to elevate SR_A’s mission while creating products that connect with a global audience.”

As part of this collaboration, SR_A will join as an investor, alongside investor-partners including Niall Horan and Cristiano Ronaldo. WHOOP will also contribute to the SR_A Black British Artist Grant and host its selected recipient for an in-house design residency, enabling emerging talent to collaborate directly with WHOOP creative teams.

To view images please visit the Digital Press Kit. The first limited-edition WHOOP x SR_A capsule will be available globally in the coming months at shop.whoop.com.

About WHOOP:

WHOOP, the human performance company, empowers people to unlock their potential and live longer, healthier lives. The WHOOP membership delivers world-class wearable technology, personalized coaching, and actionable insights across recovery, sleep, training, and health.

WHOOP wearable devices, including WHOOP 5.0 and WHOOP MG, feature groundbreaking innovations such as cardiovascular health screening (including an FDA-cleared ECG), Healthspan to measure Pace of Aging and WHOOP Age, and the first-of-its-kind wearable Blood Pressure Insights.

Founded in 2012 and headquartered in Boston, WHOOP has raised more than $400 million in venture capital and ships to 56 markets worldwide. To learn more or start a one-month free trial, visit whoop.com and connect with WHOOP on Instagram, X, Facebook, LinkedIn, and YouTube.

About SR_A:

SR_A is a Global Design Studio spanning industrial design, garment design & architecture, headquartered in London, U.K. co-founded by Samuel Ross and his long-time business partner, Yi Ng.

The studio is known for its distinct, bold visual style that merges a minimalist ethos and deeply functional decisions that blur design disciplines.

The Design Studio has received numerous global accolades, from the LVMH Design prize (2019), Three British Fashion Awards (2017-2022), two EDIDA Awards (2025), the Fuori Salone Awards (2024), & the Design Miami Basel Award for best contemporary design (2024).

The Design Studio holds numerous patents within the luxury and design sector, having collaborated with multiyear global partners including LVMH group (2019-2025), Apple Group (2020-2025), Nike Group (2016-2024) and Inditex Group (2025).

SR_A designs live permanently across global museums through direct acquisition, including The Met, The V&A, & The Design Museum.

Product designs have ranged from $200 fragrances to $150k Tourbillon watches.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260115643104/en/

Contacts

Taylor Georgeson
whoop@jacktaylorpr.com
Jack Taylor Worldwide

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye